Atara Biotherapeutics (ATRA) Asset Writedowns and Impairment (2025)

Atara Biotherapeutics (ATRA) posted Asset Writedowns and Impairment of $4.1 million for Q1 2025.

Atara Biotherapeutics (ATRA) Asset Writedowns and Impairment (2025) Analysis & Trends

Atara Biotherapeutics' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $4.1 million for Q1 2025.

  • Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $4.1 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (changed N/A YoY) and the FY2025 annual result came in at $4.1 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment was $4.1 million for Q1 2025 at Atara Biotherapeutics.
  • Across five years, Asset Writedowns and Impairment topped out at $4.1 million in Q1 2025 and bottomed at $4.1 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Atara Biotherapeutics 110.04 Mn 101.68 Mn 392,000.00

Historic Data

Download Data
DateValue
Mar 31, 2025 4.13 Mn
Mar 31, 2025 4.13 Mn